financetom
Business
financetom
/
Business
/
Robinhood rolls out desktop trading in UK to target seasoned retail investors
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Robinhood rolls out desktop trading in UK to target seasoned retail investors
May 28, 2025 12:31 AM

May 28 (Reuters) - U.S.-based online brokerage Robinhood

said on Wednesday it was expanding its desktop platform

into the UK to extend its reach among retail investors looking

for more sophisticated trading tools.

The launch comes months after the company first unveiled the

product for its U.S. customers.

WHY IT'S IMPORTANT

Retail investors are increasingly viewing trading as an

alternative career path to build wealth and strengthen their

financial health, rather than just a hobby.

To cater to their evolving needs, firms such as Robinhood

are rolling out additional features typically reserved for more

advanced traders.

Desktop trading platforms allow users to tailor their

workspace more effectively than mobile apps. Traders can monitor

multiple charts simultaneously and execute trades faster.

CONTEXT

Robinhood's desktop platform, called 'Robinhood Legend', was

launched in the U.S. in October.

The company, which is aiming to become a broader part of its

customers' finances, also launched wealth management and private

banking services in March.

The expansion could help insulate the company from the

cyclical nature of its core trading business.

KEY QUOTES

"Retail customers are a lot more engaged in the market, a

lot more thoughtful about what they're invested in, more

interested in the news and movements and passionate about the

names they hold," Jordan Sinclair, head of Robinhood UK, said in

an interview.

Many of the traders have come to realize that trading offers

a far more efficient path to achieving financial goals than

simply parking money in low-interest accounts, he added.

(Reporting by Niket Nishant in Bengaluru; Editing by Shinjini

Ganguli)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer
Sector Update: Consumer
May 30, 2025
01:06 PM EDT, 05/30/2025 (MT Newswires) -- Consumer stocks were mixed Friday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) increasing 0.8% and the Consumer Discretionary Select Sector SPDR Fund (XLY) falling 1%. In corporate news, Costco Wholesale ( COST ) reported fiscal Q3 earnings and revenue above market estimates, but the warehouse chain's comparable sales fell short...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Gap's Earnings to be Weighed Down Amid Larger-Than-Expected Tariff Headwinds, UBS Says
Gap's Earnings to be Weighed Down Amid Larger-Than-Expected Tariff Headwinds, UBS Says
May 30, 2025
01:00 PM EDT, 05/30/2025 (MT Newswires) -- Gap's (GAP) earnings through 2027 are likely to take a hit amid larger-than-projected headwinds from tariffs, UBS Securities said Friday. The apparel retailer late Thursday reiterated its net sales growth outlook of 1% to 2% for fiscal 2025. However, the guidance excluded the potential impact of tariffs, given their dynamic nature, Chief Financial...
Cartesian Therapeutics Enrolls First Participant in Phase 3 Myasthenia Gravis Study
Cartesian Therapeutics Enrolls First Participant in Phase 3 Myasthenia Gravis Study
May 30, 2025
01:02 PM EDT, 05/30/2025 (MT Newswires) -- Cartesian Therapeutics ( RNAC ) said Friday it enrolled the first participant in its phase 3 myasthenia gravis study that will evaluate Descartes-08, the company's lead cell therapy candidate for autoimmune disease. The study will evaluate Descartes-08 versus placebo given as six once-weekly outpatient infusions without preconditioning chemotherapy in about 100 participants who...
Copyright 2023-2026 - www.financetom.com All Rights Reserved